Section Arrow
TARS.NASDAQ
- Tarsus Pharmaceuticals
Quotes are at least 15-min delayed:2025/07/21 07:03 EDT
Pre Market
Last
 --
-- (--)
Bid
41
Ask
45.18
High -- 
Low -- 
Volume -- 
Regular Hours
Last
 43.25
+1.85 (+4.47%)
Day High 
45.48 
Prev. Close
41.4 
1-M High
42 
Volume 
1.26M 
Bid
41
Ask
45.18
Day Low
42.425 
Open
43.26 
1-M Low
38.515 
Market Cap 
1.74B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 40.75 
20-SMA 40.65 
50-SMA 42.2 
52-W High 57.28 
52-W Low 20.0818 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.70/-2.10
Enterprise Value
1.81B
Balance Sheet
Book Value Per Share
8.15
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
182.95M
Operating Revenue Per Share
0.30
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2.04 -0.24 -10.53%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.08 -0.995 -7.07%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0473 -0.0004 -0.84%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.19 +0.35 +5.99%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.1 +0.18 +3.04%
Quotes are at least 15-min delayed:2025/07/21 07:03 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.